AEterna Zentaris (TSX:AEZS) Total Assets : C$49.66 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Total Assets?

AEterna Zentaris's Total Assets for the quarter that ended in Dec. 2023 was C$49.66 Mil.

During the past 12 months, AEterna Zentaris's average Total Assets Growth Rate was -45.30% per year. During the past 3 years, the average Total Assets Growth Rate was -37.30% per year. During the past 5 years, the average Total Assets Growth Rate was -21.50% per year. During the past 10 years, the average Total Assets Growth Rate was -7.50% per year.

During the past 13 years, AEterna Zentaris's highest 3-Year average Total Assets Growth Rate was 141.10%. The lowest was -45.50%. And the median was -7.20%.

Total Assets is connected with ROA %. AEterna Zentaris's annualized ROA % for the quarter that ended in Dec. 2023 was -56.44%. Total Assets is also linked to Revenue through Asset Turnover. AEterna Zentaris's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

AEterna Zentaris Total Assets Historical Data

The historical data trend for AEterna Zentaris's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Total Assets Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

26.31

47.40

102.53

76.11

49.66

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															76.11	70.17	61.76	57.49	49.66

AEterna Zentaris Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

AEterna Zentaris's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	24.412	+	25.249
	=	49.66

AEterna Zentaris's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	24.412	+	25.249
	=	49.66

AEterna Zentaris (TSX:AEZS) Total Assets Explanation

Total Assets is connected with ROA %.

AEterna Zentaris's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-30.24	/	( (57.488	+	49.661)	/ 2 )
	=	-30.24	/	53.5745
	=	-56.44 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

AEterna Zentaris's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0.162	/	( (57.488	+	49.661)	/ 2 )
=	0.162	/	53.5745
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

AEterna Zentaris Total Assets Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.